Sign in

    Akash Tiwari

    Managing Director and Global Head of Biopharmaceutical Research at Jefferies

    Akash Tewari is a Managing Director and Global Head of Biopharmaceutical Research at Jefferies, specializing in equity research of SMID Cap Biotechnology companies. He covers major biopharma firms such as Eli Lilly (LLY), argenx (ARGX), Merck (MRK), and Madrigal Pharmaceuticals (MDGL), with a performance history that includes a 38% profitable recommendation rate, an average return per transaction of 3.2%, and a top single-stock call generating 400.6% return on MDGL. Tewari began his analyst career after graduating from Cornell University, previously serving as Vice President at Evercore (2015-2018) and Managing Director at Wolfe Research (2018-2021) before joining Jefferies in 2021. His credentials include recognition among the top-ranked SMID Cap Biotech analysts and extensive experience across leading investment banks.

    Akash Tiwari's questions to Alkermes (ALKS) leadership

    Akash Tiwari's questions to Alkermes (ALKS) leadership • Q4 2024

    Question

    Amy Li, on behalf of Akash Tiwari, asked about Alkermes's confidence in ALKS 2680's ability to differentiate on safety from competitors in NT1 and what the FDA requires for Phase II dose exploration before moving to Phase III.

    Answer

    CEO Richard Pops declined to comment on competitor programs but highlighted the rigorous design of Alkermes's Phase II studies (80 patients, multi-week, parallel design) to fully characterize the drug's profile. He stated the program is already differentiated by its dosing flexibility and that the orexin class has generally shown profound efficacy with mild, transient side effects.

    Ask Fintool Equity Research AI